

**THE PROGNOSTIC VALUE OF FLOW CYTOMETRY (PCM)
IN BENIGN AND MALIGNANT OVARIAN TUMORS**

Thesis

Submitted for Partial Fulfillment of
M.D. Degree in Obst. & Gyn.

by

Mohamed Ahmed Ibraheem Laban

M.B., B.Ch.; M.Sc. (Obst. & Gyn.)

Under Supervision of

Prof. Ali Elian Kalaf Allah

Prof. of Obst. & Gyn.

Faculty of Medicine, Ain Shams University

Prof. Mohammed Mabegh El Mahallawy

Prof. of Obst. & Gyn.

Faculty of Medicine, Ain Shams University

Prof. Ali Khalifa

Prof. of Biochemistry


Faculty of Medicine, Ain Shams University

Dr. Sanaa Elsa

Lecturer of Biochemistry

Faculty of Medicine, Ain Shams University

1993



[Handwritten signature]

[Handwritten signature]

[Handwritten signature]
276
652

ACKNOWLEDGEMENT

No words could express my gratitude for Prof. Dr. **ALI ELIAN** for his kindness, guidance and support throughout all the phases of this work.

Professor Dr. **M.N. EL MAHALLAWY** was so kind and helpful to me, his care and advice are unforgettable.

Professor Dr. **ALI KHALIFA** was more than a supervisor, he was a father and teacher to me, he inspired me and pushed me forward. I shall never forget his support, the chance he gave me to complete this thesis in one of the best cancer centers in the world in U.S.A.

Words are not sufficient to express my appreciation and gratitude to Dr. **SANAA EISA**. I cannot tell how much she was helpful and supportive, meticulously she revised every single word in this thesis. I am proud of working under her supervision. I hope to remain friends for the rest of my life.

My heart felt thanks to Prof. **Ezz Azzam** for supplying me with some archival blocks which helped me a lot in the results of this thesis.



Many thanks and appreciation for Associate Professor **A. El Nagaar**, Ass. Prof. of Pathology, MD Anderson Cancer Center Texas for allowing me to work with him in his excellent laboratory and acquiring the experience of dealing with paraffin tissues.

Many thanks to a lot of my Professors and colleagues who have given me much without waiting for recognition.

TABLE OF CONTENTS

* Introduction and Aim of the Work.....	1
* Review of Literature	
- Determination of the prognosis of malignant disease....	3
- Principle of Flow Cytometry.....	7
- Malignant tumors of the ovary.....	19
- The prognostic value of DNA content in ovarian carcinoma.....	32
- Comparison of the FCM data in benign, borderline and malignant ovarian tumors.....	60
- DNA ploidy of ovarian germ cell tumors.....	66
- FCM in other common Gyn. malignancies.....	68
* Patients and Methods.....	76
* Results.....	91
* Discussion.....	167
* Summary and Conclusion.....	183
* References.....	185
* Arabic Summary	

LIST OF TABLES

1.	Comparison between fresh and paraffin methods in FCM.....	18
2.	Modified WHO comprehensive classification of ovarian tumors.....	20
3.	Incidence and death rate of ovarian cancer for various countries.....	27
4.	Essential Characteristics of patients with malignant ovarian tumors.....	91
5.	Stage, pathological types and grading of malignant ovarian tumors.....	93
6.	Essential characteristics of patients with benign ovarian tumors.....	94
7.	Comparison between age, parity and menopausal status in malignant and benign ovarian tumors.....	95
8.	Comparison between preoperative serum level of CA125 in both malignant and benign ovarian tumors.....	96
9.	Comparison of DNA ploidy pattern in benign and malignant ovarian tumors.....	98
10.	Distribution of DI in malignant ovarian tumors.....	99
11.	Comparison between DI in malignant and benign ovarian tumors.....	100
12.	Comparison between SPF values in malignant and benign ovarian tumors.....	101
13.	Classification of benign and malignant ovarian tumors using different SPF cutoff levels.....	102
14.	Relapse time in malignant ovarian tumors.....	103
15.	Correlation between relapse and survival in malignant ovarian tumors.....	104
16.	Comparison between age, stage, pathological type and grade in patients with malignant ovarian tumors.....	105
17.	Correlation between patient's age Pre-op CA125, ploidy DI and SPF in malignant ovarian tumors.....	106

18.	Comparison between age, relapse, relapse time and patient's outcome.....	107
19.	Correlation between stage, pathological type and grade of malignant ovarian tumors.....	108
20.	Correlation between stage and preop CA125 level in ovarian carcinoma.....	109
21.	Correlation between stage and ploidy pattern of malignant ovarian tumors.....	110
22.	Relation between tumor stage and its DI.....	110
23a.	Correlation between tumor stage and SPF.....	111
23b.	Relation between tumor stage and its SPF.....	111
24.	Correlation between tumor stage and relapse.....	112
25.	Correlation between tumor stage and patient status.....	113
26.	Correlation between tumor pathological type and grade....	114
27.	Correlation between tumor pathological type and ploidy pattern.....	115
28.	Correlation between pathological type and tumor DI.....	116
29.	Correlation between tumor pathology and tumor SPF.....	116
30.	Correlation between tumor pathological type and recurrence.....	117
31.	Correlation between tumor pathology and patient survival.....	118
32.	Comparison between CA125 level, in well differentiated versus moderately and poorly differentiated ovarian tumors.....	118
33.	Correlation between tumor grade and ploidy pattern.....	119
34.	Comparison between DI in G1 versus G2+G3 malignant ovarian tumors.....	120
35.	Comparison of SPF value in G1 versus G2+G3 malignant ovarian tumors.....	120
36.	Correlation between tumors grade and SPF cutoff values...	121
37.	Correlation between tumors grade and relapse.....	122

38.	Correlation between tumors grade and relapse time.....	123
39.	Correlation between tumors grade and patient's outcome...	124
40.	Comparison between non diploid and diploid malignant ovarian tumors as regards CA125.....	125
41.	Correlation between preop CA125 value and patient's relapse.....	125
42.	Comparison of pre op CA125 level in survivors and non survivors.....	126
43.	Comparison between non diploid malignant tumors and diploid tumors as regard age, parity and CA125.....	126
44.	Comparison between non diploid and diploid malignant ovarian tumors and SPF values.....	127
45.	Correlation between ploidy pattern and different SPF cutoff values.....	128
46.	Correlation between ploidy pattern and relapse.....	129
47.	Correlation between ploidy pattern and relapse time.....	130
48.	Correlation between ploidy pattern and survival.....	131
49.	Correlation between tumor stage, ploidy and patient outcome.....	131
50.	Correlation between DI and SPF value in patients with malignant ovarian tumors.....	133
51.	Comparison of DI in patients with and without relapse....	134
52a.	Correlation between DI value and relapse in malignant ovarian tumors patients.....	135
52b.	Correlation between DI value and relapse in malignant ovarian tumors patients.....	135
53a.	Correlation between DI value and relapse time.....	136
53b.	Correlation between DI value and relapse time.....	137
54a.	Correlation between DI and patient outcome.....	137
54b.	Correlation between DI and patient outcome.....	138
55.	Correlaton between SPF and relapse in ovarian carcinoma..	139

56.	Correlation between SPF and patient outcome.....	139
57.	Comparison of ploidy pattern in fresh and paraffin samples.....	141
58.	Comparison between sensitivity and specificity of fresh and paraffin methods.....	141
59.	Comparison between fresh and paraffin DI.....	142
60.	Correlation between ploidy pattern of fresh aliquots and patient relapse.....	142
61.	Correlation between ploidy pattern of samples and relapse time.....	143
62.	Correlation between ploidy pattern of fresh aliquots and patient outcome.....	144
63.	Correlation between ploidy pattern of paraffin samples and relapse.....	145
64.	Correlation between ploidy pattern in paraffin samples and relapse time.....	145
65.	Correlation between paraffin ploidy and patient outcome..	146

LIST OF FIGURES

1.	Applications of flow cytometry published in the literature.....	6
2.	Schematic diagram of flow cytometer with sorting capability	8
3.	The cell cycle.....	10
4.	Diploid and aneuploid tumors	12
5.	Terms of flow cytometry and their significance	13
6.	Examples of histograms produced from ovarian carcinoma....	15
7.	Estimated incidence of cancer of leading sites in females	23
8.	Staging of ovarian carcinoma	31
9.	Comparison between benign and malignant ovarian tumors regarding ploidy pattern.....	147
10.	Comparison between benign and malignant ovarian tumors regarding SPF value	148
11.	Correlation between stage and ploidy pattern of malignant ovarian tumors	149
12.	Correlation between stage and SPF value of malignant and ovarian tumors.....	150
13.	Correlation between tumor stage and relapse of malignant ovarian tumors	151
14.	Correlation between tumor stage and survival in malignant ovarian tumors	152
15.	Correlation between tumors grade and ploidy pattern of malignant ovarian tumors.....	153
16.	Correlation between tumors grade and relapse in malignant ovarian tumors	154
17.	Correlation between tumors grade and survival in malignant ovarian tumors.....	155
18.	Correlation between tumors ploidy pattern and relapse in malignant ovarian tumors	156

19.	Correlation between ploidy pattern and survival in patients with malignant ovarian tumors	157
20.	Correlation between tumors stage, ploidy and survival in malignant ovarian tumors	158
21.	Correlation between DNA Index and replase in malignant ovarian tumors.....	159
22.	Relation between DNA Index and survival in malignant ovarian tumors	160
23.	Comparison between fresh and paraffin samples regarding ploidy pattern.....	161
24.	Comparison between sensitivity and specificity in fresh and paraffin samples.....	162
25.	Diploid pattern of ovarian tumors	163
26.	Aneuploid pattern of ovarian tumors.....	164
27.	Multiploid pattern of ovarian tumors.....	165
28.	Hypertetraploid pattern of ovarian tumors	166

INTRODUCTION AND AIM OF THE WORK

INTRODUCTION

Ovarian carcinoma is the third most common malignancy of the female genital tract, yet it is the leading cause of death for all female genital tract cancers, and the fifth most common cause of cancer death among women (Disaia, P.J., 1993).

Symptoms are non specific and frequently do not bring the patient to the attention of the gynecologist until the disease is at an advanced stage.

Various clinical and pathologic parameters have been used to help determine prognosis and therapy in patients with high stage disease.

Several parameters have been used for tumor grading such as the percentage of undifferentiated cells, architectural features and nuclear grading which are subjective to a large extent. Significant intra and interobserver variations have been noted in the diagnosis made by experienced pathologists.

It has recently been shown that the DNA content of various malignant tumors provides an objective parameter reflecting tumor biological behavior and predict prognosis. Several studies on the DNA content of ovarian tumors as

determined by absorption cytometry has shown a relationship between ploidy and prognosis as well as tumor grade and histologic types. Image cytometric studies are time consuming, labor intensive and impractical for routine clinical use.

The technique of flow cytometry (FCM) allows thousands of measurements to be made in a fraction of the time it takes to do image analysis. DNA flow cytometric studies have revealed that in advanced ovarian cancer diploid tumors are associated with better prognosis than aneuploid. Moreover, the simultaneous evaluation of DNA index, the number of aneuploid cells clones and S-phase fraction (SPF) gave additional prognostic information than the tumor ploidy alone (Schweler et al., 1993).

AIM OF THE WORK

This study will estimate the ploidy pattern and S-phase fraction (SPF) in benign and malignant ovarian tumors.

The serum levels of CA125 will be correlated with those of the flow cytometry, histopathological and clinical parameters of the patients.

The usefulness of the obtained data in the management of patients with these lesions will be declared.

REVIEW OF LITERATURE